Female Sexual Dysfunction inclusion in DSM-5 could be problematic

In this article, professor Allen Frances presents a criticism from Tamara Kayali who discusses how including Female Sexual Arousal and Female Orgasm Disorders (FSDs) in the DSM-5 could be very problematic thanks to the overzealous pharmacology industry. It's no secret that sexual dysfunction is a hot button topic and most of the pharmacology industry is focused on developing the magical pill to fix all your (real and imaginary) woes. Kayali's biggest concern is that of potential "Pharma disease mongering" - the increase in marketing for these magic treatments will increase the number of women seeking treatment for FSD not because they have it, but because they are striving to reach unreasonable societal expectations set by the pharmacology industry. Hopefully when these women seek treatment they consult a sexuality counselor who can work through their experiences and offer a more holistic approach than doctors who have been swayed by the drug companies' marketing ploys.

Read the full article here.